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ABSTRACT This study was undertaken to investigate idiopathic pulmonary fibrosis (IPF) patients’
health-related quality of life (HRQoL) and symptoms in a real-life cross-sectional study. Our secondary
aim was to create a simple identification method for patients with increased need for palliative care by
studying the relationship between modified Medical Research Council (mMRC) dyspnoea scale, HRQoL
and symptoms.
We sent a self-rating HRQoL questionnaire (RAND-36) and modified Edmonton Symptom Assessment
Scale (ESAS) to 300 IPF patients; 84% of the patients responded to these questionnaires.
The most prevalent (>80%) symptoms were tiredness, breathlessness, cough and pain in movement. An
increasing mMRC score showed a linear relationship (p<0.001) to impaired HRQoL in all dimensions of
RAND-36 and the severity of all symptoms in ESAS. Dimensions of RAND-36 fell below general
population reference values in patients with mMRC score ⩾2. The intensity of pain in movement
(p<0.001) and at rest (p=0.041), and the prevalence of chest pain (p<0.001) had a positive linear
relationship to increased mMRC score.
An increasing mMRC score reflects impaired HRQoL and a high symptom burden. In clinical practice,
the mMRC scale could be used for screening and identification of IPF patients with increased need for
palliative care.
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INTERSTITIAL LUNG DISEASE
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and severe disease of unknown cause, seen
primarily in older adults [1]. Even with recent advances in pharmacological treatment, IPF is still a disease
with a high morbidity and poor survival [2–4]. As the disease trajectory in IPF is comparable to many
advanced malignant disorders, guidelines recommend early-integrated palliative care in addition to
pharmacological treatment and referral for lung transplantation [5, 6].
Patients with IPF suffer from difficult symptoms, of which breathlessness and cough are the most
common ones [7, 8]. In addition, there is some evidence that IPF patients frequently experience pain,
although the location and mechanism of the pain have not been reported [7]. Comorbidities are frequently
reported in IPF patients, as shown in a recent study, where 88% of the patients had at least one and 30%
more than four other diagnoses [9]. The total number of comorbidities and especially the occurrence of
cardiovascular disease are associated with increased mortality [9–12].
There exist a limited number of studies on the heath-related quality of life (HRQoL) of IPF patients in a
real-life setting [13]. Most recent studies have either concentrated on pharmaceutical treatment or have
included a very limited number of patients [7, 13]. However, there are clear indications of a decreased
HRQoL in IPF patients [13, 14].
The primary aim of this cross-sectional study was to describe the HRQoL and symptom burden among
IPF patients derived from a national IPF registry (FinnishIPF). The secondary aim was the identification of
patients with increased need for palliative care by investigating the relationship between dyspnoea score
and HRQoL.
Materials and methods
Study population
The FinnishIPF study is a prospective national clinical registry study of IPF patients initiated in 2012. IPF
diagnosis is made according to the American Thoracic Society/European Respiratory Society/Japanese
Respiratory Society/Latin American Thoracic Society 2011/2015 criteria [1, 6]. In Finland, practically all
IPF patients are initially evaluated in public hospitals (university and central hospitals). The FinnishIPF
registry consists of all IPF patients from specialist centres who have given their informed consent to
participate to the study. KAUNISTO et al. [2] have published a detailed description of the FinnishIPF study.
Overall, 76% of confirmed IPF patients have given consent to participate to the study [2].
This study was initiated in April 2015, when all 300 patients registered to FinnishIPF study at that time
were contacted and asked for a written informed consent to participate in this substudy. The
questionnaires were sent to the patients with the consent form. The patients who did not respond within
2 weeks were contacted by telephone and reminded to answer to the questionnaire.
Data collection and questionnaires
Sociodemographic and disease characteristics were collected from patient records and by a separate
questionnaire. Collected data included age, sex, date of birth, marital status, living conditions, education,
physical activity, the need for help in daily activities, the date of IPF diagnosis, comorbidities and smoking
status. The participants’ exercise habits during the preceding 6 months (⩾30 min at least
moderate-intensity leisure time physical exercise, i.e. causing breathless and sweating) were asked.
The specific questionnaires of symptoms and HRQoL were modified Edmonton Symptom Assessment
Scale (ESAS), modified Medical Research Council (mMRC) dyspnoea scale and the RAND 36-Item Health
Survey (RAND-36).
The ESAS is a self-rated, numeric-rating, symptom-based scale developed for assessing the symptoms of
cancer patients [15]. ESAS measures different symptoms on a scale from 0 (no symptoms) to 10 (the
worst possible symptoms) [16, 17]. In this study, we used a modified version, including 12 questions on
symptoms, one question on general wellbeing and a standardised body diagram on which patients could
mark the areas of pain.
The mMRC scale is a self-rating tool to measure the degree of disability that breathlessness poses on
day-to-day activities on a scale from 0 to 4: 0, no breathlessness except on strenuous exercise; 1, shortness
of breath when hurrying on the level or walking up a slight hill; 2, walks slower than people of same age
on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the
level; 3, stops for breath after walking ∼100 m or after few minutes on the level; and 4, too breathless to
leave the house, or breathless when dressing or undressing [18, 19].
The RAND-36 [20] is a general HRQoL measurement tool, for which Finnish general population reference
values exist [21]. The Short Form-36, which is commonly used in IPF patients, is similar to RAND-36 [21].
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It is divided into eight health concepts, as explained by HAYS et al. [20] and AALTO [21], with scale from 0
to 100 (lower score meaning worse HRQoL). The concepts are: “physical functioning” (10 questions from
ability to move and exercise to the ability to take care of personal hygiene), “role physical” (four questions
on role limitations due to physical health), “bodily pain” (two questions), “general health” (five questions),
“vitality” (four questions on energy level and tiredness), “social functioning” (two questions), “role
emotional” (three questions on role limitations due to emotional problems) and “mental health” (five
questions on anxiety, depression and mood) during the past 4 weeks [20, 21].
Statistics and ethical aspects
The data are presented as mean±SD or n (%). The statistical significance for the hypothesis for linearity
across groups in RAND-36 domains and symptoms were determined by ANCOVA and logistic regression
analysis with an appropriate contrast (orthogonal polynomial). In the case of violation of the assumptions
(e.g. non-normality), a bootstrap-type test was used. The normality of the variables was tested by using the
Shapiro–Wilk W-test. Stata 14.1 (StataCorp LP, College Station, TX, USA) was used for the analysis.
The ethical committee of Helsinki University Central Hospital (Helsinki, Finland) approved this study
(381/13/03/01/2014). Permission to screen hospital registries for patients with IPF was approved by the
Finnish National Institute for Health and Welfare (Dnro THL/1161/5.05.01/2012). All patients who
participated to this study gave a written informed consent to participate this substudy.
Results
Of 300 registered patients, 47 were excluded: 42 did not want to participate or did not answer our
questionnaire; one received lung transplantation and one was found not to be IPF patient, so these two
also were excluded; three patients died before they answered.
Patient characteristics
The patient characteristics are shown in table 1. The mean duration of IPF at the time of the study entry
was 3.9 years. At least one comorbidity was reported in 79% (n=200) and more than two comorbidities in
30% (n=77) of the patients, respectively. 37% of the patients had performed at least moderate-intensity
leisure time physical exercise for ⩾30 min a week during the last 6 months, whereas 21% had not been
engaged in any physical exercise. A majority (65%) of the patients did not need help in everyday life,
TABLE 1 Patient characteristics
Age years 74±9
Males 165 (65%)
Duration of IPF years 3.9±2.5
Education years 10±4
Living alone 70 (28%)
Working 22 (9%)
Smoking status#
Smokers 26 (10%)
Ex-smokers 109 (43%)
Never-smokers 118 (47%)
FVC# L 3.0±0.9
FVC# % of predicted 83±17%
Comorbidities
Hypertension 105 (42%)
Coronary heart disease 64 (25%)
Diabetes 50 (20%)
Heart insufficiency 46 (18%)
COPD 43 (17%)
Cancer¶ 41 (16%)
Asthma 24 (10%)
Others 93 (37%)
No comorbidities 53 (21%)
Comorbidities n 1.8±1.5
Data are presented as mean±SD unless otherwise stated. IPF: idiopathic pulmonary fibrosis; FVC: forced
vital capacity; COPD: chronic obstructive pulmonary disease. #: smoking status and FVC were recorded at
the time of diagnosis, and other factors at the time of questionnaire; ¶: including three patients with lung
cancer.
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whereas 26% had received assistance in their daily routines. The remaining patients (9%) did not receive
help but considered themselves to be in need of it.
mMRC for breathlessness
The severity of breathlessness on exertion reported by mMRC score was 0 (no breathlessness) in 33 (13%),
1 (breathless when hurrying or walking up a hill) in 88 (35%), 2 (breathless when walking slower than
people of same age or has to stop when walking) in 75 (30%), 3 (breathlessness stops walking after
∼100 m or a few minutes) in 34 (13%) and 4 (breathless when dressing or not able to leave the house) in
23 (9%) of the patients.
RAND-36 for HRQoL
The different dimensions of HRQoL measured by RAND-36 are presented in table 2. There was a linear
relationship between impaired HRQoL and all RAND-36 dimensions and a higher mMRC score (linearity
p<0.001) (figure 1). All HRQoL dimensions of RAND-36 were significantly impaired in patients with
mMRC 2–4 as compared to the general population except “bodily pain”, which was significantly below the
general population level only in patients with mMRC score 4 (figure 1). Physical dimensions (“physical
functioning” and “role physical”) were the most impaired ones. “Role physical” derives from four
questions in the questionnaire and reflects limitations in everyday life due physical health problems [20, 21].
ESAS for symptoms
The prevalence and mean intensity of symptoms as measured by ESAS are shown in table 2. There was
positive linear relationship between the intensity of all symptoms in ESAS questionnaire and increasing
mMRC breathlessness score (figure 2).
Pain
A striking increase in pain intensity in movement (p<0.001) and, to lesser extent, at rest (p=0.041) was
found with an increased mMRC score (figure 2). The prevalence of pain in different locations of body
diagram according to mMRC groups is shown in table 3. The prevalence of chest pain and increasing
mMRC score showed a positive linear relationship (linearity p<0.001).
Discussion
This was a cross-sectional, real-life study of the quality of life and symptoms of IPF patients. Our results
show that increased breathlessness as measured by the mMRC questionnaire is related to impaired HRQoL
and symptom burden. In addition to breathlessness and cough, pain in movement was detected in a
majority of the patients. However, only chest pain had a linear relationship with increased mMRC
breathlessness score. We suggest that pain and, more importantly, chest pain, may be an underdiagnosed
symptom of IPF.
In our study, the HRQoL of IPF patients with at least moderate shortness of breath (mMRC ⩾2), was
impaired in all areas of HRQoL, especially physical function, when compared to the Finnish general
TABLE 2 Symptoms by Edmonton Symptom Assessment Scale (ESAS) questionnaire and
health-related quality of life by RAND 36-Item Health Survey (RAND-36)
ESAS Prevalence Score# RAND-36 Score
Tiredness 95% 4.7±2.6 Social functioning 72±28
Shortness of breath 88% 4.9±3.0 Mental health 72±20
Cough 85% 4.1±2.9 Bodily pain 62±27
Pain in movement 82% 3.7±2.9 Vitality 53±23
Dry mouth 79% 3.8±3.0 Role Emotional 51±42
Insomnia 67% 2.8±2.8 Physical functioning 47±29
Pain in rest 66% 2.2±2.3 General health 40±19
Depression 63% 2.1±2.4 Role Physical 31±39
Anxiety 61% 2.1±2.4
Constipation 57% 1.9±2.5
Loss of appetite 48% 1.6±2.3
Nausea 40% 1.1±1.8
Wellbeing 90% 4.4±2.4
Data are presented as mean±SD unless otherwise stated. #: numeric rating scale, 0–10.
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population [21]. Our findings are in line with an American Internet survey of 220 IPF patients in which
HRQoL was measured with PROMIS-29 [22]. A correlation between mMRC scores and all domains
except sleep disturbance was found [22]. In a small, cross-sectional, longitudinal study of 32 Japanese IPF
patients, lower scores were reported in all eight domains (HRQoL questionnaire SF-36) when compared to
the general population [13]. Similarly, in another small observational validation study of 34 IPF patients, a
decline was seen in seven of the eight measured domains of SF-36 compared to sex- and age-matched
controls [14]. That particular study also showed correlation between baseline dyspnoea index and five
SF-36 components: physical functioning, general health perceptions, vitality, social functioning and mental
health [14]. Even though there was a significant correlation between baseline dyspnoea index and pulmonary
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FIGURE 1 Health-related quality of life measured by the RAND 36-Item Health Survey according to modified Medical Research Council (mMRC)
dyspnoea scale groups. Data are presented as mean values with 95% confidence intervals. Values adjusted for age, sex, comorbidities, education
and living status. Dashed lines mark Finnish general population levels.
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function parameters, dyspnoea index seemed to predict HRQoL more sensitively than pulmonary function
parameters [14]. Dyspnoea in daily living, measured by mMRC, is also stronger prognostic parameter than
most physiological markers in the diagnostic phase of IPF [23]. NISHIYAMA et al. [23] showed that low
arterial oxygen saturation in a 6-min walk test and mMRC score were the strongest predictors of IPF
patient’s survival.
In line with the American Internet survey, increasing mMRC score was related to the symptom burden of
IPF patients in our study [22]. The three most common symptoms in our study were tiredness, shortness
of breath and cough, which are in line with earlier findings [7]. Interestingly, however, pain in movement
was the next most common symptom reported by the majority of our patients, and pain in rest was the
sixth most common symptom, present in two thirds of the patients. In a Swedish register study of
oxygen-dependent interstitial lung disease patients, pain was reported in 51% of the patients [7]. Similarly
to our findings, YOUNT et al. [22] demonstrated an association between dyspnoea severity in mMRC score
and intensity of pain. In another small observational study, no correlation between baseline dyspnoea
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index and pain index was found [14]. These differences could be related to different stage of the disease in
different study populations.
In our study, every third patient reported chest pain, which also had linear relationship to the intensity of
breathlessness measured by mMRC. Unspecified thoracic pain has been reported in pulmonary sarcoidosis
and chronic obstructive pulmonary disease but, to our knowledge, this is the first study to report chest
pain in IPF [24, 25]. The exact aetiology of chest pain in IPF falls beyond the scope of our study, and
should be an aim of further studies. However, as the relationship between chest pain and breathlessness
was maintained after adjusting for comorbidities and age, the results suggest that chest pain may be a
symptom related to IPF itself. This finding should be taken into account when considering diagnostic tests
and treatment strategies for patients with advanced IPF.
Study limitations
The cross-sectional nature of the study limits our results to a single time-point and does not allow us to
describe the changes in symptoms or HRQoL over time. Our cohort may be subjected to some selection
bias, as some patients at a very advanced stage of the disease or close to death are likely to be lost from the
cohort. Another limitation is that although the diagnosis of IPF was made by pulmonologists according to
international guidelines, there was no central confirmation of the diagnoses. The strength of our study is a
relatively large population of IPF patients in different phases of disease trajectory, evaluated by several
assessment tools in real-life setting, and a high response rate.
Conclusions
Pain is a relatively common symptom in IPF. In particular, chest pain is related to increasing mMRC
score. This could indicate a causal relationship between chest pain and progressive IPF, but further studies
are necessary to confirm and explain these findings. Our results show that mMRC not only reflects
breathlessness in patients with IPF but indicates HRQoL and overall symptom burden. The HRQoL was
significantly deteriorated and symptom burden rose in patients with mMRC score ⩾2. Thus, mMRC could
be used as a simple screening tool for palliative care needs of IPF patients.
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